Person: ÇELİK, BURAK
Search Results
Apolipoprotein E4 Mediated Targeting of Blood Brain Barrier Using Nano-Micellar Metal Chelators for Treatment of Alzheimer’s Disease
2015-08-06, BAHADORİ, FATEMEH, ÇELİK, BURAK, Kazdal, Fatma, KUŞMAN, TUBA, BAHADORİ, FATEMEH, ÇELİK, BURAK, KUŞMAN, TUBA
Evaluation of Wound Healing Potential of New Composite Liposomal Films Containing Coenzyme Q10 and D-Panthenyl Triacetate as Combinational Treatment.
2021-02-13T00:00:00Z, Sağıroğlu, Ali Asram, Çelik, Burak, Güler, Eray Metin, Koçyiğit, ABDÜRRAHİM, Özer, Özgen, ASRAM SAĞIROĞLU, ALİ, ÇELİK, BURAK, KOÇYİĞİT, ABDÜRRAHİM
Plant extracts as metal chelators for treatment of Alzheimer’s disease
2015-08-06, Kazdal, Fatma, ÇELİK, BURAK, BAHADORİ, FATEMEH, Ertaş, Abdulselam, ÇELİK, BURAK, BAHADORİ, FATEMEH
Intraocular pressure in infants and its association with hormonal changes with vaginal birth versus cesarean section.
2016-12-01, Elbay, AHMET, CELIK, U, CELIK, BURAK, OZER, OF, KILIC, GÖKHAN, AKKAN, JC, BAYRAKTAR, BİLGE, KAYMAK, NZ, ELBAY, AHMET, ÇELİK, BURAK, ÖZER, ÖMER FARUK, KILIC, GÖKHAN, BAYRAKTAR, BILGE
Hedeflendirilmiş Nanoilaçlar
2017-09-01, ÖNYÜKSEL, Hayat, BAHADORİ, FATEMEH, ÇELİK, BURAK, BAHADORİ, FATEMEH, ÇELİK, BURAK
Optimization of piribedil mucoadhesive tablets for efficient therapy of Parkinson-s disease: physical characterization and ex vivo drug permeation through buccal mucosa
2017-01-01, Celik, BURAK, Ozdemir, Samet, Demirkoz, Asli Barla, Uner, Melike, ÇELİK, BURAK
Objective: The aim of this study was optimization of buccal piribedil (PR) mucoadhesive tablets to improve its low bioavailability and provide controlled release for the treatment of Parkinson-s disease.
INFLUENCE OF VEHICLES AND PENETRATION ENHANCERS ON ANTI-INFLAMMATORY EFFECT OF 18-beta GLYCYRRHETINIC ACID: KINETIC MODELLING OF DRUG RELEASE, IN VIVO AND EX VIVO EXPERIMENTS
2020-07-01T00:00:00Z, Karaman, Ecem Fatma, ÇELİK, BURAK, Ozdemir, Samet, Tekkeli, Evrim Kepekci, Demirkoz, Asli Barla, Gonullu, Umit, Uner, Melike, ÇELİK, BURAK, TEKKELİ, ŞERİFE EVRİM
Topical formulations of 18-beta glycyrrhetinic acid (18-beta GA) were designed for use in relieving inflammatory and painful conditions of the skin. Formulations were containing penetration enhancers that differ in penetration enhancing mechanisms. Anti-inflammatory effects of formulations and effects of penetration enhancers on penetration and permeation of the drug through rat skin were investigated. The total amount of 18-beta GA permeated from the base oil/water emulsion (53.19 +/- 22.25 mcg/cm(2) ) was approximately twice higher than the base oleaginous cream (29.17 +/- 3.85 mcg/cm(2)) while there was no 18-beta GA permeation from the base hydrogel formulation to the skin (p < 0.05). Incorporation of propylene glycol was generally found to increase 18-beta GA permeation to the skin. The highest oedema inhibiting activity was achieved in the oil/water emulsion containing propylene glycol followed by the base oil/water emulsion without a penetration enhancer (p < 0.05). This result was consistent with the ex vivo study. Limonene and oleic acid were found to be insufficient in 18-beta GA permeation to the skin.
Therapeutic Potential of Drug Delivery by Means of Lipid Nanoparticles: Reality or Illusion?
2017-01-01, Uner, Melike, Damgali, Sukran, Ozdemir, Samet, Celik, BURAK, ÇELİK, BURAK
Background: Solid lipid nanoparticles (SLN) are colloidal drug carrier systems that contribute several properties required from a sophisticated drug delivery system for increasing drug bioavailability and providing effective therapy. Many advantages of SLN have been reported over traditional dosage forms and their colloidal counterparts since the early 1990s. They were optimized for oral drug delivery for the first time. The first SLN formulations were produced by reducing particle size of solid lipid microparticles by spray congealing technique in the late 1980s. Then, studies have been continued investigating for their different administration routes else including parenteral, transdermal, ocular, nasal, respiratory etc.
Eplerenone nanoemulsions for treatment of hypertension. Part II: Physical stability assessment and in vivo study
2018-06-01T00:00:00Z, Ozdemir, Samet, Celik, BURAK, Sumer, Engin, Acar, Ebru Turkoz, Uner, Melike, ÇELİK, BURAK
The aim of the present complimentary study was to investigate physical stability of eplerenone (EP) loaded nanoemulsions and to evaluate their pharmacokinetic profiles after subcutaneous application to Sprague Dawley rats. Nanoemulsions were prepared by using high shear homogenization and ultrasonication techniques. All formulations were having 0.1% EP. They were obtained in 150.6 nm-205.8 nm size range. Physical stability of nanoemulsions was monitored storing them at different thermal conditions for 120 days. Droplet size was confirmed to be affected by storage temperature when it slightly changed at 4 +/- 2 degrees C and 25 +/- 2 degrees C. 40 +/- 2 degrees C was found not to be suitable as a storage condition in general. Pharmacokinetic study on physically stable formulations demonstrated that subcutaneously applied eplerenone solution showed that AUC(0)->infinity and C-max were 1.62 and 2.05 folds higher than eplerenone solution after oral administration. Additionally, AUC(0)->infinity and C-max were significantly increased in the case of nanoemulsions prepared with Brij (R) 35 and Tween (R) 80. Relative bioavailability of the drug was found to be remarkably increased after administration of formulations stabilized with Tween (R) 80. Results suggested that eplerenone loaded nanoemulsions may provide an alternative application way for efficient management of hypertension attacks.
Design, preparation and characterization of liposomal formulation used for wound healing
2017-10-04, ASRAM SAĞIROĞLU, ALİ, ÇELİK, BURAK, ÖZDEMIR, S, ASRAM SAĞIROĞLU, ALİ, ÇELİK, BURAK